These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36388465)

  • 1. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
    Greer YE; Hernandez L; Fennell EMJ; Kundu M; Voeller D; Chari R; Gilbert SF; Gilbert TSK; Ratnayake S; Tang B; Hafner M; Chen Q; Meerzaman D; Iwanowicz E; Annunziata CM; Graves LM; Lipkowitz S
    Cancer Res Commun; 2022 Oct; 2(10):1144-1161. PubMed ID: 36388465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
    Fennell EMJ; Aponte-Collazo LJ; Wynn JD; Drizyte-Miller K; Leung E; Greer YE; Graves PR; Iwanowicz AA; Ashamalla H; Holmuhamedov E; Lang H; Karanewsky DS; Der CJ; Houry WA; Lipkowitz S; Iwanowicz EJ; Graves LM
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00993. PubMed ID: 35929764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLPP deficiency ameliorates neurodegeneration caused by impaired mitochondrial protein synthesis.
    Rumyantseva A; Popovic M; Trifunovic A
    Brain; 2022 Mar; 145(1):92-104. PubMed ID: 35240691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Caseinolytic Protease P: A Possible Novel Prognostic Marker and Therapeutic Target in Cancer.
    Cormio A; Sanguedolce F; Pesce V; Musicco C
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ClpP/ClpX deficiency impairs mitochondrial functions and mTORC1 signaling during spermatogenesis.
    Guo C; Xiao Y; Gu J; Zhao P; Hu Z; Zheng J; Hua R; Hai Z; Su J; Zhang JV; Yeung WSB; Wang T
    Commun Biol; 2023 Oct; 6(1):1012. PubMed ID: 37798322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
    Zhang J; Luo B; Sui J; Qiu Z; Huang J; Yang T; Luo Y
    Biochem Pharmacol; 2022 Oct; 204():115232. PubMed ID: 36030831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrates and interactors of the ClpP protease in the mitochondria.
    Mabanglo MF; Bhandari V; Houry WA
    Curr Opin Chem Biol; 2022 Feb; 66():102078. PubMed ID: 34446368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the mitochondrial matrix peptidase ClpP in muscle cells causes mitochondrial dysfunction and decreases cell proliferation.
    Deepa SS; Bhaskaran S; Ranjit R; Qaisar R; Nair BC; Liu Y; Walsh ME; Fok WC; Van Remmen H
    Free Radic Biol Med; 2016 Feb; 91():281-92. PubMed ID: 26721594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent ClpP agonists with anticancer properties bind with improved structural complementarity and alter the mitochondrial N-terminome.
    Mabanglo MF; Wong KS; Barghash MM; Leung E; Chuang SHW; Ardalan A; Majaesic EM; Wong CJ; Zhang S; Lang H; Karanewsky DS; Iwanowicz AA; Graves LM; Iwanowicz EJ; Gingras AC; Houry WA
    Structure; 2023 Feb; 31(2):185-200.e10. PubMed ID: 36586405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma.
    Wang P; Zhang T; Wang X; Xiao H; Li H; Zhou LL; Yang T; Wei B; Zhu Z; Zhou L; Yang S; Lu X; Zhang Y; Huang Y; Gan J; Yang CG
    Cell Chem Biol; 2022 Sep; 29(9):1396-1408.e8. PubMed ID: 35905743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of conserved mitochondrial CLPP and its functions lead to different phenotypes in plants and other organisms.
    Huang S; Petereit J; Millar AH
    Plant Signal Behav; 2020 Dec; 15(12):1831789. PubMed ID: 33073672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
    Fennell EMJ; Aponte-Collazo LJ; Pathmasiri W; Rushing BR; Barker NK; Partridge MC; Li YY; White CA; Greer YE; Herring LE; Lipkowitz S; Sumner SCJ; Iwanowicz EJ; Graves LM
    Front Pharmacol; 2023; 14():1136317. PubMed ID: 37063293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.
    Zhang R; Wang P; Wei B; Chen L; Song X; Pan Y; Li J; Gan J; Zhang T; Yang CG
    Eur J Med Chem; 2023 Oct; 258():115577. PubMed ID: 37352796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds.
    Ózsvári B; Sotgia F; Lisanti MP
    Aging (Albany NY); 2020 May; 12(11):10162-10179. PubMed ID: 32452826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction.
    Kou X; Ding H; Li L; Chao H
    Ann Transl Med; 2021 Sep; 9(18):1463. PubMed ID: 34734015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mitochondrial protease ClpP is a druggable target that controls VSMC phenotype by a SIRT1-dependent mechanism.
    Paredes F; Williams HC; Liu X; Holden C; Bogan B; Wang Y; Crotty KM; Yeligar SM; Elorza AA; Lin Z; Rezvan A; San Martin A
    Redox Biol; 2024 Jul; 73():103203. PubMed ID: 38823208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60.
    Kumar R; Chaudhary AK; Woytash J; Inigo JR; Gokhale AA; Bshara W; Attwood K; Wang J; Spernyak JA; Rath E; Yadav N; Haller D; Goodrich DW; Tang DG; Chandra D
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35653190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.
    Ozsvari B; Bonuccelli G; Sanchez-Alvarez R; Foster R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2017 Dec; 9(12):2610-2628. PubMed ID: 29253841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.